Phase 2
N=83
Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01827787 ↗Enrolled (actual)
83
Serious AEs
42.2%
Results posted
Feb 2019
Primary outcome: Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Eribulin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dana-Farber Cancer Institute
- Primary completion
- May 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Response Rate (ORR) |
35.6; 13.2 | 0.42 |
| SECONDARY Progression-Free Survival (PFS) |
6.2; 4.0 | — |
| SECONDARY Time to First Response (TTR) |
10.6; NA | — |
| SECONDARY Duration of Overall Response (DOR) |
6.5; 1.9 | — |
| SECONDARY Percentage of Participants With Grade 1-3 Treatment-Related Peripheral Sensory Neuropathy |
36.1 | — |
| SECONDARY Percentage of Participants With Grade 1-3 Treatment-Related Peripheral Motor Neuropathy |
22.9 | — |
| SECONDARY Functional Assessment of Cancer Therapy-Breast Cancer Subscale (FACT-BCS) Change Score From Baseline |
1.0; 0.6; 0.1; 0.6; 1.8; 1.1 | — |
| SECONDARY Functional Assessment of Cancer Therapy-Neurotoxicity Subscale (FACT-Ntx) Change Score From Baseline |
-0.1; -0.3; -1.6; -4.5; -1.8; -1.6 | — |
Summary
Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years. Long term complete responses are observed only for a minority of MBC patients (2-5%) and MBC remains an incurable disease for most patients. Eribulin is a chemotherapy approved by the US FDA in November of 2010 to treat patients with MBC who have received at least two prior chemotherapy regimens. In this research study, the investigators are looking to see how well eribulin helps participants with MBC in an earlier-line setting. Eribulin works by interfering with cancer cell division, growth and spread.
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically proven invasive breast cancer, locally recurrent or metastatic, with at least one measureable lesion according to RECIST v1.1
- Hormone receptor positive or hormone receptor negative HER2-negative disease
- Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at least 14 days prior to initiation of protocol therapy)
- Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable
- No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days prior to initiation of protocol therapy
- Must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy
- Must have recovered from reversible effects of prior therapies to no more than grade 1 toxicity, with the exception of alopecia
- Agree to use adequate contraception for the duration of study participation
Exclusion Criteria
- Pregnant or breastfeeding
- Prior treatment with eribulin
- Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer unless diagnosed and definitively treated at least 3 years before enrollment in this study
- Clinically significant cardiovascular impairment
- Active brain metastases or unevaluated neurologic symptoms suggestive of brain metastases
- Pulmonary dysfunction requiring the use of oxygen
- Prior organ allograft requiring immunosuppression
- HIV positive on combination antiretroviral therapy
- Pre-existing grade 3 or 4 neuropathy
- Hypersensitivity to halichondrin B or halichondrin B chemical derivative
- Uncontrolled intercurrent illness
- Inability to read in English
Data sourced from ClinicalTrials.gov (NCT01827787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.